{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06227377",
            "orgStudyIdInfo": {
                "id": "QTX3034-001"
            },
            "organization": {
                "fullName": "Quanta Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "QTX3034 in Patients With KRAS G12D Mutation",
            "officialTitle": "A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-patients-with-kras-mutation"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-18",
            "studyFirstSubmitQcDate": "2024-01-18",
            "studyFirstPostDateStruct": {
                "date": "2024-01-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Quanta Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1a: QTX3034 monotherapy dose-escalation",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3034 will be administered at protocol defined dose based on cohort assignment",
                    "interventionNames": [
                        "Drug: QTX3034"
                    ]
                },
                {
                    "label": "Part 1b: QTX3034 combination with cetuximab dose-escalation",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment",
                    "interventionNames": [
                        "Drug: QTX3034",
                        "Combination Product: Cetuximab"
                    ]
                },
                {
                    "label": "Part 2: QTX3034 monotherapy dose-expansion",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment",
                    "interventionNames": [
                        "Drug: QTX3034"
                    ]
                },
                {
                    "label": "Part 3: QTX3034 combination with cetuximab dose-expansion",
                    "type": "EXPERIMENTAL",
                    "description": "QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment",
                    "interventionNames": [
                        "Drug: QTX3034",
                        "Combination Product: Cetuximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "QTX3034",
                    "description": "QTX3034 will be administered at protocol defined dose",
                    "armGroupLabels": [
                        "Part 1a: QTX3034 monotherapy dose-escalation",
                        "Part 1b: QTX3034 combination with cetuximab dose-escalation",
                        "Part 2: QTX3034 monotherapy dose-expansion",
                        "Part 3: QTX3034 combination with cetuximab dose-expansion"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Cetuximab",
                    "description": "Cetuximab will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 1b: QTX3034 combination with cetuximab dose-escalation",
                        "Part 3: QTX3034 combination with cetuximab dose-expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Dose Limiting Toxicities (DLTs)",
                    "description": "DLTs will be defined as the occurrence of any of the toxicities as described in the protocol",
                    "timeFrame": "up to 21 days"
                },
                {
                    "measure": "Number of participants with Treatment-emergent Adverse Events (TEAEs)",
                    "description": "Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab",
                    "timeFrame": "up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "QTX3034 pharmacokinetic parameters in plasma",
                    "description": "Plasma concentration data for QTX3034 will be used to evaluate PK parameters such as maximum concentration (Cmax), minimum concentration (Cmin), time to attain Cmax (Tmax), area under the concentration-time curve (AUC), elimination half-life (t1\u20442).",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "The ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on RECIST 1.1.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "Duration of response (DoR) is defined as the time between first evidence of objective response and disease progression (as measured by RECIST 1.1) or death, whichever occurs earlier, in subjects who achieve CR or PR.",
                    "timeFrame": "up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic\n* Part 1: - Advanced solid tumors with at least 1 prior systemic therapy\n* Evaluable or Measurable disease per RECIST 1.1.\n* Parts 2 and 3: Measurable disease per RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior treatment with a KRAS inhibitor\n* Active brain metastases or carcinomatous meningitis\n* History of other malignancy within 2 years\n* Significant cardiovascular disease\n* Disease or disorder that may pose a risk to patient's safety\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Quanta Therapeutics Clinical Trials",
                    "role": "CONTACT",
                    "phone": "415-599-3892",
                    "email": "clinicaltrials@quantatx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Duke University",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sabina Wlazlo",
                            "role": "CONTACT",
                            "phone": "919-668-1861",
                            "email": "sabina.wlazlo@duke.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "MD Anderson",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ly Nguyen",
                            "role": "CONTACT",
                            "phone": "713-563-1930",
                            "email": "LMNguyen1@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Isabel Jimenez, RN, MSN",
                            "role": "CONTACT",
                            "phone": "210-593-5265",
                            "email": "isabel.jimenez@startsa.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "University of Utah, Huntsman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Susan Sharry",
                            "role": "CONTACT",
                            "phone": "801-585-3453",
                            "email": "susan.sharry@hci.utah.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "NEXT Oncology Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Blake Patterson",
                            "role": "CONTACT",
                            "phone": "703-783-4505",
                            "email": "bpatterson@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}